Top Markets
#1 Black Phoenix Black Phoenix +829.59%
#2 pipedog pipedog +41.28%
#3 PondCoin PondCoin +35.42%
#4 Bless Bless +35.40%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.74%
#6 SAFEcoin SAFEcoin +26.00%
#7 Beam Beam +24.62%
#8 Seeker Seeker +21.01%
#9 Magma Finance Magma Finance +20.64%
#10 YFSX YFSX +16.15%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Rank in Stocks #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Share Price
$64.97
Last synced: 2024-05-20
Market Cap
$1.97B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Alpine Immune Sciences, Inc. (ALPN)

Category

Healthcare
Revenue for Alpine Immune Sciences, Inc. (ALPN)
Revenue in Mar 2024 TTM: $56.52M
According to Alpine Immune Sciences, Inc. latest financial reports the company's current revenue (TTM) is $56.52M. In 2022 the company made a revenue of $30.06M an increase over the revenue in the year 2021 that was $23.44M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Alpine Immune Sciences, Inc. from 2012 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $56.52M -4.00%
2023 $58.88M 95.84%
2022 $30.06M 28.24%
2021 $23.44M 151.13%
2020 $9.34M 436.49%
2019 $1.74M 146.81%
2018 $705.00K -59.27%
2017 $1.73M -41.32%
2016 $2.95M 499.59%
2015 $492.00K 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 22,235.59%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 10,553.19%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 27,755.71%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 3,841.90%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH